Liraglutide (0.6 mg/kg) reduced kidney damage, improved kidney function, and lowered lipid levels in obese mice by inhibiting the CaMKKβ/AMPK signaling pathway — effects that were partially reversed by an AMPK agonist.
CaMKKβ/AMPK pathwayLiraglutide's kidney protection works by inhibiting this signaling pathway — confirmed when an AMPK agonist partially reversed the protective effects
What the researchers found
Liraglutide (0.6 mg/kg for 12 weeks) protected against HFD-induced kidney injury by reducing serum lipids, improving kidney function markers, reversing kidney pathology, and inhibiting the CaMKKβ/AMPK signaling pathway. Bortezomib (AMPK agonist) partially reversed these effects.
Why it matters
Obesity-related kidney disease is a growing epidemic with no targeted treatment. Demonstrating that liraglutide directly protects kidneys through a defined molecular pathway (not just through weight loss) could expand its clinical indications to include kidney protection in obese patients.
The numbers in context
36 mice in 6 groups (n=6). High-fat diet-induced nephropathy model. CaMKKβ/AMPK pathway activation confirmed as mechanism.
How the study worked
36 C57BL/6J male mice in 6 groups (n=6). Obesity-related kidney disease induced by 12 weeks HFD, then 12 weeks of liraglutide (0.6 mg/kg) or bortezomib (200 μg/kg). Measured serum lipids, kidney function (Scr, BUN, urinary protein), kidney histology (H&E, PAS staining), and CaMKKβ/AMPK pathway activation (IHC, western blot, RT-qPCR).
Who was studied
C57BL/6J male mice with high-fat diet-induced nephropathy
What this study cannot tell us
Small animal study (6 mice per group). Only 12 weeks of treatment may not capture long-term kidney outcomes. The use of bortezomib (primarily a proteasome inhibitor) as an AMPK agonist adds complexity to interpretation. Human kidney disease involves factors beyond what HFD models capture.
How to read the evidence
Preliminary evidence from a small animal study (36 mice, 6 per group). The mechanism is supported by the reversal experiment but lacks human clinical validation.
When this study was published
Published in 2024; contributes to the growing evidence for GLP-1 agonist kidney protection.
The bigger picture
GLP-1 agonists continue to reveal organ-protective effects beyond glucose control. The kidney protection via CaMKKβ/AMPK pathway adds to evidence of cardiovascular, liver, and brain protection — building the case that GLP-1 agonists are multi-organ protective drugs.
Questions still open
- Does the CaMKKβ/AMPK mechanism explain kidney benefits observed in human clinical trials of GLP-1 agonists?
- Would higher liraglutide doses or longer treatment provide greater kidney protection?
- Is the kidney-protective effect independent of liraglutide's weight-loss effect?
Common questions
Can liraglutide prevent kidney disease from obesity?
What is the CaMKKβ/AMPK pathway?
Read the original research
Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
Renal failure, 46(1), 2351473
Citation
Xuan, Yingli; Ding, Ting-Ting; Mao, Xiao-Lei; Pang, Shiqing; He, Ruibin; Qin, Li; Yuan, Jiang Zi. (2024). Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.. Renal failure, 46(1), 2351473. https://doi.org/10.1080/0886022X.2024.2351473